Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07092566 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

R.E.C.K vs Exparel in Robotic Nephrectomy

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. 2 versions Re-verified since Jan 16, 2026, no change to tracked fieldsv6-v7
  2. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Nov 2025 to Nov 14, 2025
    • Site details revised
    v5
  3. Start date: Sep 2025 to Nov 2025v4
  4. Re-verified, no change to tracked fieldsv3
  5. Interventions: Exparel (Drug), ropivacaine + epineprine + clonidine + ketoralac (Drug) to Clonidine HCL (Drug), Epinephrine (Drug), Exparel (Drug), Ketorolac (Drug), Ropivacaine HCL (Drug)
    • Secondary endpoints revised (8)
    v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of the study is to evaluate the efficacy of R.E.C.K (ropivacaine epinephrine clonidine ketorolac) vs Exparel during robotic partial and radical nephrectomy in a single institution, prospective, randomized trial. The study will evaluate post operative Numerical Rating Score (NRS) pain scores, post operative pain medication intake (opioids and over-the-counter pain medicines) and length of stay across the two patient cohorts. The findings will help to inform whether the increased cost of Exparel when compared to R.E.C.K is justified.
Trial Details
NCT Number NCT07092566
Lead Sponsor Wake Forest University Health Sciences
Collaborators: Atrium Health Levine Cancer Institute
Conditions
(from sponsor)		 Renal Carcinoma, Nephrectomy / Methods, Pain Management
Related terms Agnosia, Carcinoma, Renal Cell
Enrollment 170 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov